- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer ; volume:40 ; number:04 ; year:2019 ; pages:461-462
Indian journal of medical & paediatric oncology ; 40, Heft 04 (2019), 461-462
- Beteiligte Personen und Organisationen
-
Noronha, Vanita
Mehta, Prashant
Malik, Prabhat Singh
Patel, Amol
- DOI
-
10.4103/ijmpo.ijmpo_210_19
- URN
-
urn:nbn:de:101:1-2021081213154754297764
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Noronha, Vanita
- Mehta, Prashant
- Malik, Prabhat Singh
- Patel, Amol
Ähnliche Objekte (12)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma